{
  "symbol": "REGN",
  "year": 2023,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.2054,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.49
  },
  "top_positive": [
    {
      "sent": "Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2023 2022 2023 2022 Dupixent and Kevzara net product sales $ 3,193.3 $ 2,418.2 $ 8,645.7 $ 6,509.1 Regeneron's share of collaboration profits $ 995.6 $ 686.7 $ 2,564.8 $ 1,700.6 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation (132.6) (78.7) (314.2) (180.7) One-time payment in connection with amendment to the Antibody License and Collaboration Agreement \u2014 (56.9) \u2014 (56.9) Regeneron's share of profits in connection with commercialization of antibodies $ 863.0 $ 551.1 $ 2,250.6 $ 1,463.0 Regeneron's share of collaboration profits as a percentage of Dupixent and Kevzara net product sales 27% 23% 26% 22% 44 Table of Contents The increase in our share of profits in connection with commercialization of antibodies during the three and nine months ended September\u00a030, 2023, compared to the same periods in 2022, was driven by higher profits associated with Dupixent sales, partly offset by the impact of the amendment to the LCA.",
      "score": 0.9833
    },
    {
      "sent": "Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2023 2022 2023 2022 Dupixent and Kevzara net product sales $ 3,193.3 $ 2,418.2 $ 8,645.7 $ 6,509.1 Regeneron's share of collaboration profits $ 995.6 $ 686.7 $ 2,564.8 $ 1,700.6 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation (132.6) (78.7) (314.2) (180.7) One-time payment in connection with amendment to the Antibody License and Collaboration Agreement \u2014 (56.9) \u2014 (56.9) Regeneron's share of profits in connection with commercialization of antibodies $ 863.0 $ 551.1 $ 2,250.6 $ 1,463.0 Regeneron's share of collaboration profits as a percentage of Dupixent and Kevzara net product sales 27%\nsults may fluctuate from quarter to quarter and will depend on, among other factors, the net sales of our products; the scope and progress of our research and development efforts; the timing of certain expenses; the continuation of our collaborations, in particular with Sanofi and Bayer, including our share of collaboration profits from sales of commercialized products and the amount of reimbursement of our research and development expenses that we receive from collaborators; and the amount of income tax expense we incur, which is partly dependent on the profits or losses we earn in each of the countries in which we operate.",
      "score": 0.9831
    },
    {
      "sent": "These factors include, by way of example: \u2022 net product sales of our marketed products (as recorded by us or our collaborators), in particular EYLEA, EYLEA HD, Dupixent, and Libtayo, as well as our overall operating results; \u2022 if any of our product candidates or our new indications for our marketed products receive regulatory approval, net product sales of, and profits from, these product candidates and new indications; \u2022 market acceptance of, and the market share for, our marketed products, especially EYLEA, EYLEA HD, Dupixent, and Libtayo; \u2022 whether our net product sales and net profits underperform, meet, or exceed the expectations of investors or analysts; \u2022 announcement of actions by the FDA or foreign regulatory authorities or their respective advisory committees regarding our, or our collaborators', or our competitors', currently pending or future application(s) for regulatory approval of product candidate(s) or new indications for marketed products; \u2022 announcement of submission of an application for regulatory approval of one or more of our, or our competitors', product candidates or new indications for marketed products; \u2022 progress, delays, or results in clinical trials of our or our competitors' product candidates or new indications for marketed products; \u2022 announcement of technological innovations or product candidates by us or competitors; \u2022 claims by others that our products or technologies infringe their patents; \u2022 challenges by others to our patents in the EPO and in the USPTO; \u2022 public concern as to the safety or effectiveness of any of our marketed products or product \nrs plus Dr.",
      "score": 0.9819
    }
  ],
  "top_negative": [
    {
      "sent": "Other Regulatory and Litigation Risks \u2022 If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.",
      "score": -0.9559
    },
    {
      "sent": "We and our collaborators would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, supply chain interruptions or constraints (including with respect to natural gas and other raw materials), contaminations, fire, climate change, natural disasters, acts of war or terrorism, or other problems.",
      "score": -0.9531
    },
    {
      "sent": "Further, we may be unable to pursue our research and development efforts if the relevant facility were to cease operations due to fire, climate change, natural disasters, acts of war or terrorism, or other disruptions.",
      "score": -0.9371
    }
  ],
  "forward_snippets": [
    "roduct candidates; the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; unanticipated expenses; the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "28 Table of Contents (d) The Company is solely responsibl\ning, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; unanticipated expenses; the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "28 Table of Contents (d) The Company is solely responsible for the development and commercialization of Praluent in the United States and Sanofi is responsible for the development a\nguidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "Intellia will lead the design of the editing methodology, we will lead the design of the targeted viral vector delivery approach, and the parties share costs equally.",
    "We expect to continue to incur substantial expenses related to our research and development activities, a portion of which we expect to be reimbursed by our collaborators."
  ],
  "curated_text": "Symbol: REGN. Year: 2023. Period: Q1. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2023 2022 2023 2022 Dupixent and Kevzara net product sales $ 3,193.3 $ 2,418.2 $ 8,645.7 $ 6,509.1 Regeneron's share of collaboration profits $ 995.6 $ 686.7 $ 2,564.8 $ 1,700.6 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation (132.6) (78.7) (314.2) (180.7) One-time payment in connection with amendment to the Antibody License and Collaboration Agreement \u2014 (56.9) \u2014 (56.9) Regeneron's share of profits in connection with commercialization of antibodies $ 863.0 $ 551.1 $ 2,250.6 $ 1,463.0 Regeneron's share of collaboration profits as a percentage of Dupixent and Kevzara net product sales 27% 23% 26% 22% 44 Table of Contents The increase in our share of profits in connection with commercialization of antibodies during the three and nine months ended September\u00a030, 2023, compared to the same periods in 2022, was driven by higher profits associated with Dupixent sales, partly offset by the impact of the amendment to the LCA. Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2023 2022 2023 2022 Dupixent and Kevzara net product sales $ 3,193.3 $ 2,418.2 $ 8,645.7 $ 6,509.1 Regeneron's share of collaboration profits $ 995.6 $ 686.7 $ 2,564.8 $ 1,700.6 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation (132.6) (78.7) (314.2) (180.7) One-time payment in connection with amendment to the Antibody License and Collaboration Agreement \u2014 (56.9) \u2014 (56.9) Regeneron's share of profits in connection with commercialization of antibodies $ 863.0 $ 551.1 $ 2,250.6 $ 1,463.0 Regeneron's share of collaboration profits as a percentage of Dupixent and Kevzara net product sales 27%\nsults may fluctuate from quarter to quarter and will depend on, among other factors, the net sales of our products; the scope and progress of our research and development efforts; the timing of certain expenses; the continuation of our collaborations, in particular with Sanofi and Bayer, including our share of collaboration profits from sales of commercialized products and the amount of reimbursement of our research and development expenses that we receive from collaborators; and the amount of income tax expense we incur, which is partly dependent on the profits or losses we earn in each of the countries in which we operate. These factors include, by way of example: \u2022 net product sales of our marketed products (as recorded by us or our collaborators), in particular EYLEA, EYLEA HD, Dupixent, and Libtayo, as well as our overall operating results; \u2022 if any of our product candidates or our new indications for our marketed products receive regulatory approval, net product sales of, and profits from, these product candidates and new indications; \u2022 market acceptance of, and the market share for, our marketed products, especially EYLEA, EYLEA HD, Dupixent, and Libtayo; \u2022 whether our net product sales and net profits underperform, meet, or exceed the expectations of investors or analysts; \u2022 announcement of actions by the FDA or foreign regulatory authorities or their respective advisory committees regarding our, or our collaborators', or our competitors', currently pending or future application(s) for regulatory approval of product candidate(s) or new indications for marketed products; \u2022 announcement of submission of an application for regulatory approval of one or more of our, or our competitors', product candidates or new indications for marketed products; \u2022 progress, delays, or results in clinical trials of our or our competitors' product candidates or new indications for marketed products; \u2022 announcement of technological innovations or product candidates by us or competitors; \u2022 claims by others that our products or technologies infringe their patents; \u2022 challenges by others to our patents in the EPO and in the USPTO; \u2022 public concern as to the safety or effectiveness of any of our marketed products or product \nrs plus Dr. Top negative sentences: Other Regulatory and Litigation Risks \u2022 If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims. We and our collaborators would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, supply chain interruptions or constraints (including with respect to natural gas and other raw materials), contaminations, fire, climate change, natural disasters, acts of war or terrorism, or other problems. Further, we may be unable to pursue our research and development efforts if the relevant facility were to cease operations due to fire, climate change, natural disasters, acts of war or terrorism, or other disruptions. Forward-looking snippets: roduct candidates; the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; unanticipated expenses; the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition. 28 Table of Contents (d) The Company is solely responsibl\ning, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; unanticipated expenses; the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition. 28 Table of Contents (d) The Company is solely responsible for the development and commercialization of Praluent in the United States and Sanofi is responsible for the development a\nguidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition. Intellia will lead the design of the editing methodology, we will lead the design of the targeted viral vector delivery approach, and the parties share costs equally. We expect to continue to incur substantial expenses related to our research and development activities, a portion of which we expect to be reimbursed by our collaborators."
}